Back to search
FDAFDA · Food and drugs·Recall number Z-1025-2024

BD BBL Sensi Disc Cefuroxime- 30 ug, used for semi-quantitative in vitro susceptibility testing. Catalog Number 231621®

Published February 14, 2024 · Recall initiated: January 8, 2024

Summary

FDA records medical device Class II recall Z-1025-2024, published February 14, 2024 and initiated January 8, 2024. Recalling firm: Becton Dickinson & Co.; Status: Ongoing; Reported quantity: 2,363,168 total units; Lot: Catalog No. 231621® UDI-DI 30382902316214 Lots 2304487 3093372 3158087 3223379 1335657 2004439 2090487 2147701 2210631. Class II means possible temporary or medically reversible effects, or a remote probability of serious health consequences.

Status when published: Ongoing — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.

What's the hazard

There is a possibility of reproducibility, accuracy, and/or QC failures in antibiotic susceptibility testing (AST) for H. influenzae. This may cause product discard, delayed results, or additional adverse diagnostic outcomes, such as a delay in diagnosis, the selection of inappropriate antibiotics, or extended duration of antibiotic exposure and the treatment process.

What to do

Voluntary: Firm initiated · Letter

Get an email when a new FDA recall like this is published

Free. We only write when there's a new recall that matches. Unsubscribe in one click.

Recall details

Manufacturer
Becton Dickinson & Co.
Distributor
Domestic distribution nationwide. International distribution worldwide.
Lot
Catalog No. 231621® UDI-DI 30382902316214 Lots 2304487 3093372 3158087 3223379 1335657 2004439 2090487 2147701 2210631
Risk classification
Class II
Area (FDA)
device
Country
United States

Related recalls

Questions about this recall

Was BD BBL Sensi Disc Cefuroxime- 30 ug, used for semi-quantitative in vitro susceptibility testing. Catalog Number 231621® recalled?

Yes. FDA published recall Z-1025-2024 on February 14, 2024. Reported hazard: There is a possibility of reproducibility, accuracy, and/or QC failures in antibiotic susceptibility testing (AST) for H. influenzae. This may cause product discard, delayed results, or additional adverse diagnostic outcomes, such as a delay in diagnosis, the selection of inappropriate antibiotics, or extended duration of antibiotic exposure and the treatment process.

What should I do if I have this product?

Voluntary: Firm initiated · Letter